EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

Targeting Rab‐RILPL interactions as a strategy to downregulate pathogenic LRRK2 in Parkinson's disease

Krista K Alexander, Yahaira Naaldijk, Rachel Fasiczka, Besma Brahmia, Tiancheng Chen, Sabine Hilfiker, Eileen J Kennedy iD

Journal of Peptide Science · 2024

DOI: 10.1002/psc.3563 ↗

At a glance

Journal article in Journal of Peptide Science, 2024. Written by Krista K Alexander and 6 co-authors. Institution: Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA, USA. Major MEDLINE topics: Parkinson Disease. Cited 3 times so far (Crossref); 35 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Michael J. Fox Foundation for Parkinson's Research.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Familial Parkinson's disease (PD) is frequently linked to multiple disease‐causing mutations within Leucine‐Rich Repeat Protein Kinase 2 (LRRK2), leading to aberrant kinase activity. Multiple pathogenic effects of enhanced LRRK2 activity have been identified, including loss of cilia and centrosomal cohesion defects. When phosphorylated by LRRK2, Rab8a and Rab10 bind to phospho‐specific RILPL effector proteins. RILPL‐mediated accumulation of pRabs proximal to the mother centriole is critical for initiating deficits in ciliogenesis and centrosome cohesion mediated by LRRK2. We hypothesized that Rab‐derived phospho‐mimics may serve to block phosphorylated Rab proteins from docking with RILPL in the context of hyperactive LRRK2 mutants. This would serve as an alternative strategy to downregulate pathogenic signaling mediated by LRRK2, rather than targeting LRRK2 kinase activity itself. To test this theory, we designed a series of constrained peptides mimicking phosphorylated Switch II derived from Rab8. These RILPL interacting peptides, termed RIP, were further shown to permeate cells. Further, several peptides were found to bind RILPL2 and restore ciliogenesis and centrosomal cohesion defects in cells expressing PD‐associated mutant LRRK2. This research demonstrates the utility of constrained peptides as downstream inhibitors to target pathogenic LRRK2 activity and may provide an alternative approach to target specific pathways activated by LRRK2.

Subjects

MeSH terms (MEDLINE)

Parkinson DiseaseHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MutationPeptidesPhosphorylationSignal Transductionrab GTP-Binding Proteins

Author keywords

LRRK2LRRK2 inhibitorsParkinson's diseasecentrosomal cohesionciliogenesisconstrained peptides

Substances

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2PeptidesLRRK2 protein, humanRAB8A protein, humanrab GTP-Binding Proteins

Authors and institutions

  • Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA, USA.
  • Department of Anesthesiology, Rutgers New Jersey Medical School, Newark, NJ, USA.

ORCID profiles: Eileen J Kennedy

Funding

  • Michael J. Fox Foundation for Parkinson's Research

Cite

APA

Alexander, K. K., Naaldijk, Y., Fasiczka, R., Brahmia, B., Chen, T., Hilfiker, S., & Kennedy, E. J. (2024). Targeting Rab‐RILPL interactions as a strategy to downregulate pathogenic LRRK2 in Parkinson's disease. Journal of Peptide Science. https://doi.org/10.1002/psc.3563

Vancouver

Alexander KK, Naaldijk Y, Fasiczka R, Brahmia B, Chen T, Hilfiker S, et al. Targeting Rab‐RILPL interactions as a strategy to downregulate pathogenic LRRK2 in Parkinson's disease. Journal of Peptide Science. 2024. doi:10.1002/psc.3563

BibTeX
@article{Alexander2024,
  author = {Alexander, Krista K and Naaldijk, Yahaira and Fasiczka, Rachel and Brahmia, Besma and Chen, Tiancheng and Hilfiker, Sabine and Kennedy, Eileen J},
  title = {Targeting Rab‐RILPL interactions as a strategy to downregulate pathogenic LRRK2 in Parkinson's disease},
  journal = {Journal of Peptide Science},
  year = {2024},
  doi = {10.1002/psc.3563}
}
Start for free →